What ABBOTT LABORATORIES's SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Liquidity and Cash Position91 · importance in its document · 10-Q · 2026Q3
At September 30, 2026, cash and cash equivalents were $4.052 billion, down from $8.522 billion at December 31, 2025. Long-term debt was $29.451 billion and current debt was $1.708 billion, compared with $9.896 billion and $3.033 billion,…
Interest Expense Increase76 · importance in its document · 10-Q · 2026Q3
Net interest expense increased $253 million to $297 million in the third quarter of 2026. For the first nine months, it increased $521 million to $664 million. The increases primarily reflected interest on debt incurred to finance the…
Exact Sciences Acquisition71 · importance in its document · 10-Q · 2026Q3
Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded the purchase primarily with $20.0 billion of long-term debt issued in March 2026…
Strategic Business Separation71 · importance in its document · 8-K exhibit · 21 Oct 2026
Abbott intends to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to Abbott shareholders. The Nutrition company is expected to have approximately $8.5 billion…
Revenue Performance and Mix64 · importance in its document · 10-Q · 2026Q3
Third-quarter 2026 net sales rose 14.5% year over year to $13.013 billion, or 14.8% excluding foreign exchange; nine-month sales rose 11.9% to $36.770 billion, or 10.5% excluding foreign exchange. In the first nine months, Medical Devices…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

Liquidity and Cash PositionImportance 91
At September 30, 2026, cash and cash equivalents were $4.052 billion, down from $8.522 billion at December 31, 2025. Long-term debt was $29.451 billion and current debt was $1.708 billion, compared with $9.896 billion…
Interest Expense IncreaseImportance 76
Net interest expense increased $253 million to $297 million in the third quarter of 2026. For the first nine months, it increased $521 million to $664 million. The increases primarily reflected interest on debt…
Exact Sciences AcquisitionImportance 71
Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded the purchase primarily with $20.0 billion of long-term debt…
Revenue Performance and MixImportance 64
Third-quarter 2026 net sales rose 14.5% year over year to $13.013 billion, or 14.8% excluding foreign exchange; nine-month sales rose 11.9% to $36.770 billion, or 10.5% excluding foreign exchange. In the first nine…
Operating Income and MarginsImportance 58
Third-quarter operating earnings fell 34% to $1.358 billion from $2.057 billion, while nine-month operating earnings declined 24% to $4.396 billion from $5.802 billion. Third-quarter net sales grew 14% to $13.013…
Operating Expense TrendsImportance 58
Third-quarter research and development expense rose 17% to $2.579 billion from $2.207 billion. Third-quarter selling, general, and administrative expense increased 40% to $4.266 billion from $3.051 billion. For the…
Operating Cash Flow and CapexImportance 48
Net cash from operating activities totaled $5.5 billion in the first nine months of 2026, approximately $700 million below the prior-year period. The decline primarily reflected legal-settlement payments, higher…
Geographic Market CommentaryImportance 48
For the first nine months of 2026, total U.S. sales increased 17.7%, while total international sales increased 5.9% excluding foreign exchange. In Core Laboratory, diagnostic test sales on the Alinity platform…
DOJ Infant Formula InvestigationImportance 47 · +1 more on this subject
Abbott resolved investigations by the U.S. Department of Justice and complaints in September 2026 concerning its U.S. manufacturing of powdered infant formula. The DOJ and several states had partially intervened in a…
Research and Development InvestmentImportance 47
R&D expense increased $154 million, or 20.1%, to $920 million in the third quarter of 2026. For the first nine months, R&D expense rose $372 million, or 16.9%, to $2.6 billion. The increases primarily reflected the…
Income Tax Rate ChangesImportance 42
First-nine-month 2026 taxes on earnings included approximately $540 million of expense related to a deferred tax asset recognized as a significant non-cash tax benefit in a prior year, compared with approximately $460…
Infant Formula LitigationImportance 40
Abbott faces lawsuits alleging that cow’s-milk-containing preterm infant formula and human milk fortifier caused necrotizing enterocolitis (NEC) and failed to warn of the risk. In September 2026, Abbott reached…

8-K filings last 12 months

Press release attached to an 8-K21 Oct 2026 · 8-K
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Strategic Business Separation · Revenue Performance and Mix
Guidance reaffirmed21 Oct 2026 · 8-K Item 2.02 · Routine · rule score 15
“Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance – Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent – Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS…”
Read from the attached exhibit: Revenue Performance and Mix · Exact Sciences Acquisition · Operating Income and Margins
Press release attached to an 8-K20 Aug 2026 · 8-K
Read from the attached exhibit: Infant Formula Litigation · End-Market Demand Trends · Products and Technology
Guidance raised16 Jul 2026 · 8-K Item 2.02 · Flagged · rule score 60
“Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance – Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent – Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS…”
Read from the attached exhibit: Geographic Market Commentary · Income Tax Rate Changes · Acquisition / Partnership / Divestiture
Board change27 Apr 2026 · 8-K Item 5.02 · Routine · rule score 10
“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
Guidance revised (direction not stated)16 Apr 2026 · 8-K Item 2.02 · Flagged · rule score 55
“Updates Guidance to Reflect Acquisition of Exact Sciences – First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent – Completed acquisition of Exact Sciences, establishing Abbott as a leader in…”
New debt9 Mar 2026 · 8-K Items 1.01, 2.03 · Flagged · rule score 50
“On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes…”
New debt26 Feb 2026 · 8-K Item 1.01 · Flagged · rule score 50
“Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior…”
Guidance issued22 Jan 2026 · 8-K Item 2.02 · Routine · rule score 25
“Issues 2026 Financial Outlook – Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent – Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent…”
Board change12 Dec 2025 · 8-K Item 5.02 · Routine · rule score 10
“On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
Agreement to acquire a business20 Nov 2025 · 8-K Item 1.01 · Routine · rule score 45
“On November 19, 2025, Abbott Laboratories, an Illinois corporation (“Abbott”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), and Badger…”

Earlier reports

10-Q · 2026Q2filed 28 Jul 2026
Debt and Liquidity Position · Operating Cash Flow and Capex · Exact Sciences Acquisition

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.